Clinical and pathogenic significance of S100A4 overexpression in systemic sclerosis.
Christopher P DentonShiwen XuFenge ZhangRory H MacleanKristina Elizabeth Neergaard ClarkSigne BorchertRizwan I HussainJörg KlingelhöferJonas HallénVoon H OngPublished in: Annals of the rheumatic diseases (2023)
Our findings provide compelling evidence for a profibrotic role for S100A4 in SSc and suggest that serum level may be a biomarker of major organ manifestations and disease severity. This study supports examining the therapeutic potential of targeting S100A4 in SSc.